iTeos Therapeutics (ITOS) Price & Analysis

Compare

193 Followers

ITOS Stock Chart & Stats

Day’s Range― - ―

52-Week Range$4.80 - $18.13

Previous CloseN/A

Volume59.28K

Average Volume (3M)1.29M

Market Cap

$386.95M

Enterprise Value-$257.17M

Total Cash (Recent Filing)$520.37M

Total Debt (Recent Filing)$5.05M

Price to Earnings (P/E)―

Beta1.69

Next Earnings

Nov 05, 2025

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-1.81

Shares Outstanding38,273,796

10 Day Avg. Volume1,026,361

30 Day Avg. Volume1,290,249

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)0.00

Price to Sales (P/S)0.00

P/FCF Ratio0.00

Enterprise Value/Market Cap-0.66

Enterprise Value/Revenue-7.35

Enterprise Value/Gross Profit-7.41

Enterprise Value/Ebitda1.74

Forecast

1Y Price Target

$10.41

Price Target Upside3.07% Upside

Rating ConsensusHold

Number of Analyst Covering6

Bulls Say, Bears Say

Bulls Say

AcquisitionThe acquisition by Concentra Biosciences is likely to close with the top two shareholders, EcoR1 and Tang Capital, in a positive position.

Cash PositionITeos ended 1Q:25 with cash of $624 million, indicating a strong cash position before the acquisition.

Strategic ReviewInvestors reacted positively to the news of belrestotug’s termination, with the stock showing an increase, likely due to the announcement of a strategic review to maximize shareholder value.

Bears Say

Legal RisksThe deal lacks a provision for shareholder vote, which may lead to legal disputes similar to other Concentra deals.

Pipeline DevelopmentThere is low confidence that any early-stage immuno-oncology asset will add value for iTeos in the next year, as the investor bar for excitement is high.

Shareholder ExpectationsThe terms of the acquisition may not meet broader shareholder expectations, being approximately 30% to previously disclosed iTeos cash.

iTeos Therapeutics News

iTeos Therapeutics downgraded to Neutral from Overweight at Piper Sandler

Piper Sandler analyst Edward Tenthoff downgraded iTeos Therapeutics (ITOS) to Neutral from Overweight with a price target of...

17d ago

ITOS

Vor Bio appoints Cumbo, Detheux to board of directors

Vor Bio (VOR) announced the appointment of Alexander Cumbo and Michel Detheux, Ph.D., to its Board of Directors,...

17d ago

VOR

ITOS

iTeos to be acquired by Concentra for $10.047 per share in cash plus CVR

iTeos Therapeutics (ITOS) entered into a definitive merger agreement whereby Concentra Biosciences will acquire iTeos for $10.047 in...

17d ago

ITOS

iTeos Therapeutics Faces Challenges Amid Collaboration Termination

Iteos Therapeutics, Inc. ( ($ITOS) ) has released its Q2 earnings. Here is a breakdown of the information...

18h ago

ITOS

iTeos Therapeutics Announces Merger with Concentra Biosciences

iTeos Therapeutics ( ($ITOS) ) has issued an announcement. On July 18, 2025, iTeos Therapeutics entered into a...

17d ago

ITOS

GSK and Iteos Therapeutics’ Promising Phase 3 Study on NSCLC Treatment

GlaxoSmithKline (($GSK)), GlaxoSmithKline plc (UK) (($GB:GSK)), Iteos Therapeutics, Inc. (($ITOS)) announced an update on their ongoing clinical study....

21d ago

GSK

ITOS

GSK and iTeos Therapeutics Advance Phase 3 NSCLC Study with Belrestotug and Dostarlimab

GlaxoSmithKline (($GSK)), GlaxoSmithKline plc (UK) (($GB:GSK)), Iteos Therapeutics, Inc. (($ITOS)) announced an update on their ongoing clinical study....

23d ago

GSK

ITOS

iTeos Therapeutics Holds Annual Stockholders Meeting

The latest announcement is out from iTeos Therapeutics ( ($ITOS) ). iTeos Therapeutics, Inc. held its Annual Meeting...

2M ago

ITOS

Tim Van Hauwermeiren Resigns from iTeos Board

iTeos Therapeutics ( ($ITOS) ) has shared an update. On June 1, 2025, Tim Van Hauwermeiren resigned from...

2M ago

ITOS

iTeos Therapeutics: Strategic Wind Down to Maximize Shareholder Value Amid Limited Pipeline Prospects

Analyst Daina Graybosch of Leerink Partners reiterated a Hold rating on iTeos Therapeutics (ITOS – Research Report), boosting...

2M ago

ITOS

iTeos Therapeutics downgraded to Equal Weight at Wells Fargo on wind down

As previously reported, Wells Fargo analyst Eva Fortea Verdejo downgraded iTeos Therapeutics (ITOS) to Equal Weight from Overweight...

2M ago

ITOS

iTeos Therapeutics downgraded to Equal Weight from Overweight at Wells Fargo

Wells Fargo downgraded iTeos Therapeutics (ITOS) to Equal Weight from Overweight with a $12 price target Published first...

2M ago

ITOS

iTeos Therapeutics Stock (ITOS) Booms 24% as it Winds Down and Sells Cancer Treatments

Shares in iTeos Therapeutics rocketed 24% higher today as it announced plans to wind-down its operations. Cancer Treatments...

2M ago

ITOS

iTeos Therapeutics downgraded to Neutral at Wedbush after wind down decision

As previously reported, Wedbush analyst David Nierengarten downgraded iTeos Therapeutics (ITOS) to Neutral from Outperform with a price...

2M ago

ITOS

ITOS FAQ

What was Iteos Therapeutics, Inc.’s price range in the past 12 months?

Iteos Therapeutics, Inc. lowest stock price was $4.80 and its highest was $18.13 in the past 12 months.

What is Iteos Therapeutics, Inc.’s market cap?

Iteos Therapeutics, Inc.’s market cap is $386.95M.

When is Iteos Therapeutics, Inc.’s upcoming earnings report date?

Iteos Therapeutics, Inc.’s upcoming earnings report date is Nov 05, 2025 which is in 90 days.

How were Iteos Therapeutics, Inc.’s earnings last quarter?

Iteos Therapeutics, Inc. released its earnings results on Aug 07, 2025. The company reported -$1.807 earnings per share for the quarter, missing the consensus estimate of -$1.278 by -$0.529.

Is Iteos Therapeutics, Inc. overvalued?

According to Wall Street analysts Iteos Therapeutics, Inc.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Iteos Therapeutics, Inc. pay dividends?

Iteos Therapeutics, Inc. does not currently pay dividends.

What is Iteos Therapeutics, Inc.’s EPS estimate?

Iteos Therapeutics, Inc.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Iteos Therapeutics, Inc. have?

Iteos Therapeutics, Inc. has 38,273,796 shares outstanding.

What happened to Iteos Therapeutics, Inc.’s price movement after its last earnings report?

Iteos Therapeutics, Inc. reported an EPS of -$1.807 in its last earnings report, missing expectations of -$1.278. Following the earnings report the stock price went down -3.112%.

Which hedge fund is a major shareholder of Iteos Therapeutics, Inc.?

Currently, no hedge funds are holding shares in ITOS

iTeos Therapeutics Stock Smart Score

Neutral

Fundamentals

Return on Equity

-23.68%

Trailing 12-Months

Asset Growth

4.62%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Iteos Therapeutics, Inc.

iTeos Therapeutics (ITOS) is a biotechnology company dedicated to the discovery and development of novel cancer immunotherapies. The company operates primarily in the pharmaceutical and biotechnology sectors, focusing on creating innovative treatments that harness the body's immune system to fight cancer. Its core products are centered around immuno-oncology drug candidates designed to target specific pathways involved in immune resistance and tumor growth.

iTeos Therapeutics (ITOS) Earnings & Revenues

Historic Earnings Reports

ITOS Stock 12 Month Forecast

Average Price Target

$10.41

▲(3.07% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"4":"$4","11":"$11","18":"$18","7.5":"$7.5","14.5":"$14.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":12,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$12.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":10.41,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$10.41</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":8,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$8.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[4,7.5,11,14.5,18],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jun<br/>2024","6":"Nov<br/>2024","9":"Mar<br/>2025","12":"Jul<br/>2025","25":"Jul<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,10,10.153846153846153,10.307692307692308,10.461538461538462,10.615384615384615,10.76923076923077,10.923076923076923,11.076923076923077,11.23076923076923,11.384615384615385,11.538461538461538,11.692307692307693,11.846153846153847,{"y":12,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,10,10.031538461538462,10.063076923076924,10.094615384615384,10.126153846153846,10.157692307692308,10.18923076923077,10.22076923076923,10.252307692307692,10.283846153846154,10.315384615384616,10.346923076923076,10.378461538461538,{"y":10.41,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,10,9.846153846153847,9.692307692307692,9.538461538461538,9.384615384615385,9.23076923076923,9.076923076923077,8.923076923076923,8.76923076923077,8.615384615384615,8.461538461538462,8.307692307692307,8.153846153846153,{"y":8,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":9.91,"date":1698796800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.27,"date":1709251200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.78,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.74,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.46,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.85,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.81,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.55,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.68,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.26,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.63,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.5,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >